Redefining Cancer Care

Pan-tumor therapies

What are pan-tumor treatments?

Pan-tumor (also called tumor-agnostic or tumor-independent) treatments can be used to treat a variety of cancer types regardless of the cancer’s histology or location in the body.¹,² They target the specific genomic driver or molecular alteration of the cancer, which causes it to grow or spread.³

They belong to a branch of personalized medicine known as precision oncology. This uses genomic profiling (laboratory analysis of human genetic material) to identify a patient’s biomarker information and assist in determining treatment for that individual.²

How are the genomic features of cancer detected?

Researchers are currently looking into many more potential treatments, which may be available in the near future if successful. This research is examining various genomic features of cancer that have the potential to become pan-tumor treatments.⁶

Historically, cancer treatments were approved based on their effect in specific cancer types, such as chemotherapy for lung cancer or breast cancer.

How do pan-tumor treatments differ from other cancer treatments?

Biomarker testing techniques, such as ‘next generation sequencing’ (NGS) of cancer genes and other scientific tests, are used to identify if a specific genomic abnormality (mutation) is present in a tumor, called genomic profiling.⁴

Are pan-tumor treatments ready now, and what’s on the horizon?

The recent availability of three pan-tumor treatments is leading to a significant shift in how people with cancer are treated.³

These approved pan-tumor treatments are pembrolizumab (given as an intravenous infusion by a specialist every three or six weeks), larotrectinib (taken as tablets or capsules twice a day), and entrectinib (taken as tablets once a day) for the treatment of various solid tumors (not blood tumors such as leukemia).³

Researchers are currently looking into many more potential treatments, which may be available in the near future if successful. This research is examining various genomic features of cancer that have the potential to become pan-tumor treatments.⁶

A Pan-Tumor Briefing Sheet by the following contributors:

Dr Bernard Avouac, MD, Consultant Market Access and Reimbursement, C2A, Paris, France; Antonella Cardone, Director, European Cancer Patient Coalition (ECPC); Professor Antoine Italiano, Head of the Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France; Professor Jesus Garcia-Foncillas, MD, PHD, Director, Oncohealth Institute and University Hospital “Fundacion Jimenez Diaz” Autonomous University of Madrid, Spain; Professor Ulrik Lassen, MD, PHD, Head, Department of Oncology, Rigshospitalet, Professor of Oncology, University of Copenhagen, Denmark; Dr Lydia Makaroff, CEO, Fight Bladder Cancer, UK, and Vice-President, World Bladder Cancer Patient Coalition, Belgium; Dr Pietro Presti, MBA, PHD, Head, Department of Oncology, Rigshospitalet, Professor of Oncology, University of Copenhagen, Denmark; Dr Lydia Makaroff, CEO, Fight Bladder Cancer, UK, and Vice-President, World Bladder Cancer Patient Coalition, Belgium; Dr Pietro Presti, MBA, PHD, Head, Department of Oncology, Rigshospitalet, Professor of Oncology, University of Copenhagen, Denmark; Dr Lydia Makaroff, CEO, Fight Bladder Cancer, UK, and Vice-President, World Bladder Cancer Patient Coalition, Belgium; Dr Pietro Presti, MBA, PHD, Head, Department of Oncology, Rigshospitalet, Professor of Oncology, University of Copenhagen, Denmark; Dr Lydia Makaroff, CEO, Fight Bladder Cancer, UK, and Vice-President, World Bladder Cancer Patient Coalition, Belgium; Dr Pietro Presti, MBA, PHD, Head, Department of Oncology, Rigshospitalet, Professor of Oncology, University of Copenhagen, Denmark; Dr Lydia Makaroff, CEO, Fight Bladder Cancer, UK, and Vice-President, World Bladder Cancer Patient Coalition, Belgium.
“One size fits all” medicines only help a subset of cancer patients. Patients need governments to ensure availability of molecular testing to allow doctors to personalize cancer care for patients, identifying the right treatment for the right patient at the right time. The pan-tumor approach could help achieve this faster, as we can identify those people more likely to benefit from treatment.”

Antonella Cardone, Director, European Cancer Patient Coalition (ECPC)

What are the benefits to patients?

Biomarker-directed care or precision oncology, along with a review of a patient’s medical history, helps to select the right treatment for the right person with potential for improved treatment outcomes.

Some people can avoid treatments that don’t work for them.

This means that they can also avoid the potential unnecessary side-effects and their management.

What are the benefits for healthcare systems?

With improved biomarker testing and access to personalized cancer therapies, there is real potential to improve patient outcomes, while lowering overall healthcare costs.

Seeking the most effective treatment for each patient, within a country’s economic limits, can contribute to healthcare sustainability and minimize the impact on healthcare budgets.

What are the hurdles to improving access to diagnostic testing?

One size does not fit all. The heterogeneity of healthcare systems around the world, along with mixed availability of diagnostic technologies and infrastructure at time of diagnosis all complicate access to pan-tumor medicines.

Some barriers include low awareness among government and regulatory policy makers, clinicians and patient advocates of the concept of pan-tumor medicines and the value these bring to patients.

By developing action plans that work for policy makers, clearer communication, improved education, and with input from patients, then a future where genomic profiling becomes routine practice can be achieved.

References